<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Biol Chem</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Biol. Chem</journal-id>
<journal-id journal-id-type="hwp">jbc</journal-id>
<journal-id journal-id-type="pmc">jbc</journal-id>
<journal-id journal-id-type="publisher-id">JBC</journal-id>
<journal-title-group>
<journal-title>The Journal of Biological Chemistry</journal-title>
</journal-title-group>
<issn pub-type="ppub">0021-9258</issn>
<issn pub-type="epub">1083-351X</issn>
<publisher>
<publisher-name>American Society for Biochemistry and Molecular Biology</publisher-name>
<publisher-loc>11200 Rockville Pike, Suite 302, Rockville, MD 20852-3110, U.S.A.</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28389555</article-id>
<article-id pub-id-type="pmc">5448085</article-id>
<article-id pub-id-type="publisher-id">R116.765388</article-id>
<article-id pub-id-type="doi">10.1074/jbc.R116.765388</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Minireviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Targeting of microbe-derived metabolites to improve human health: The next frontier for drug discovery</article-title>
<alt-title alt-title-type="short">MINIREVIEW: Drugging microbial enzymology in human health</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Brown</surname>
<given-names>J. Mark</given-names>
</name>
<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/content/292/21/8560/suppl/DCAuthor_profile_JMB"></ext-link>
<xref ref-type="aff" rid="aff1">
<sup>‡</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>§</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hazen</surname>
<given-names>Stanley L.</given-names>
</name>
<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/content/292/21/8560/suppl/DCAuthor_profile_SLH"></ext-link>
<xref ref-type="aff" rid="aff1">
<sup>‡</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>§</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>¶</sup>
</xref>
<xref ref-type="corresp" rid="cor2">
<sup>2</sup>
</xref>
</contrib>
<aff id="aff1">From the Departments of <label>‡</label>Cellular and Molecular Medicine and </aff>
<aff id="aff2"><label>¶</label>Cardiovascular Medicine and </aff>
<aff id="aff3"><label>§</label>Center for Microbiome and Human Health, Cleveland Clinic, Cleveland, Ohio 44195</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>1</label> To whom correspondence may be addressed: <addr-line>9500 Euclid Ave., NC-10, Cleveland Clinic, Cleveland, OH 44195.</addr-line> Tel.: <phone>216-444-8340</phone>; Fax: <fax>216-444-9404</fax>; E-mail: <email>brownm5@ccf.org</email>.</corresp>
<corresp id="cor2"><label>2</label> To whom correspondence should be addressed: <addr-line>9500 Euclid Ave., NC-10, Cleveland Clinic, Cleveland, OH 44195.</addr-line> Tel.: <phone>216-445-9763</phone>; Fax: <fax>216-636-0392</fax>; E-mail: <email>hazens@ccf.org</email>.</corresp>
<fn fn-type="edited-by">
<p>Edited by Ruma Banerjee</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>26</day>
<month>5</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>7</day>
<month>4</month>
<year>2017</year>
</pub-date>
<volume>292</volume>
<issue>21</issue>
<fpage>8560</fpage>
<lpage>8568</lpage>
<permissions>
<copyright-statement>© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>The American Society for Biochemistry and Molecular Biology, Inc.</copyright-holder>
</permissions>
<self-uri content-type="pdf" xlink:href="zbc02117008560.pdf"></self-uri>
<abstract>
<p>Recent advances in metabolomic and genome mining approaches have uncovered a poorly understood metabolome that originates solely or in part from bacterial enzyme sources. Whether living on exposed surfaces or within our intestinal tract, our microbial inhabitants produce a remarkably diverse set of natural products and small molecule metabolites that can impact human health and disease. Highlighted here, the gut microbe-derived metabolite trimethylamine <italic>N</italic>-oxide has been causally linked to the development of cardiovascular diseases. Recent studies reveal drugging this pathway can inhibit atherosclerosis development in mice. Building on this example, we discuss challenges and untapped potential of targeting bacterial enzymology for improvements in human health.</p>
</abstract>
<kwd-group>
<kwd>atherosclerosis</kwd>
<kwd>cardiovascular disease</kwd>
<kwd>drug discovery</kwd>
<kwd>metabolomics</kwd>
<kwd>microbiome</kwd>
</kwd-group>
<funding-group>
<award-group id="award1">
<funding-source>
<institution-wrap>
<institution>Foundation for the National Institutes of Health
</institution>
<institution-id institution-id-type="open-funder-registry">10.13039/100000002</institution-id>
</institution-wrap>
</funding-source>
<award-id>R01 HL122283</award-id>
<award-id>P50 AA024333</award-id>
<award-id>R01 HL103866</award-id>
<award-id>P01 HL076491</award-id>
<award-id>R01DK10600</award-id>
<award-id>R01HL126827</award-id>
</award-group>
</funding-group>
</article-meta>
</front>
</article>
</pmc-articleset>